about
Evidence that bank vole PrP is a universal acceptor for prionsMolecular Mechanisms of Chronic Wasting Disease Prion Propagation.Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice.Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients.Mouse models for studying the formation and propagation of prions.Successes and challenges in phenotype-based lead discovery for prion diseasesHeterogeneous seeding of HET-s(218-289) and the mutability of prion structures.Prion protein-specific antibodies-development, modes of action and therapeutics applicationStructure-based drug design identifies polythiophenes as antiprion compounds.The elusive role of the prion protein and the mechanism of toxicity in prion disease.Use of a 2-aminothiazole to Treat Chronic Wasting Disease in Transgenic MiceAntiprion Activity of DB772 and Related Monothiophene- and Furan-Based Analogs in a Persistently Infected Ovine Microglia Culture SystemDifferent 2-Aminothiazole Therapeutics Produce Distinct Patterns of Scrapie Prion Neuropathology in Mouse Brains.Two alternative pathways for generating transmissible prion disease de novo.Modulation of Creutzfeldt-Jakob disease prion propagation by the A224V mutationA cationic tetrapyrrole inhibits toxic activities of the cellular prion protein.Prions: Beyond a Single Protein.Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice.Integrated Organotypic Slice Cultures and RT-QuIC (OSCAR) Assay: Implications for Translational Discovery in Protein Misfolding Diseases.Quinacrine promotes replication and conformational mutation of chronic wasting disease prions.Bioassays and Inactivation of Prions.Mammalian prions and their wider relevance in neurodegenerative diseases.Insights from Therapeutic Studies for PrP Prion Disease.Developing Therapeutics for PrP Prion Diseases.Exploring Anti-Prion Glyco-Based and Aromatic Scaffolds: A Chemical Strategy for the Quality of Life.Optimization of Aryl Amides that Extend Survival in Prion-Infected Mice.Towards authentic transgenic mouse models of heritable PrP prion diseases.Pyrene conjugation and spectroscopic analysis of hydroxypropyl methylcellulose compounds successfully demonstrated a local dielectric difference associated with in vivo anti-prion activity.The many shades of prion strain adaptation.Identification of a Compound That Disrupts Binding of Amyloid-β to the Prion Protein Using a Novel Fluorescence-based Assay.Anti-prion activity found in beetle grub hemolymph of Trypoxylus dichotomus septentrionalis.A dominant-negative mutant inhibits multiple prion variants through a common mechanism.Human stem cell-derived astrocytes replicate human prions in a PRNP genotype-dependent manner.Structural heterogeneity and intersubject variability of Aβ in familial and sporadic Alzheimer's disease.Biology and Genetics of PrP Prion Strains.A Bioluminescent Cell Assay to Quantify Prion Protein Dimerization
P2860
Q27330039-39E52F79-5916-42E9-9B8B-2BD12BAFD876Q31161627-14C26826-5996-439E-BBE0-08B981CBC878Q33925689-B3656094-B5FD-4091-96B6-FDD45A7B3A2FQ33925710-CE2554ED-3EFA-4121-9250-4CA223F4DCE6Q33931079-F8CB856D-9D45-4725-9183-2FA45A06B62FQ34104276-42D3A6B6-8C3E-4DC4-9911-69B50F526A15Q34307230-825686A4-E817-4257-AEEC-B870EDAFC388Q34423386-672A5F93-32BF-477F-972D-49DD26AB3897Q34488418-F524B02E-2EBE-4FB8-9F3E-5AF3455E954FQ35624321-7C4A1646-6854-4585-B79D-586AB9E6FCC5Q35999953-F348A375-11AD-47EF-8FB6-C0106E93CFAEQ36068573-833C0C5F-6FCE-487E-9C5C-FB3D15DA5A29Q36077668-7EB28903-7E8A-46EA-849A-976E9504B023Q36270558-2DF8F7FA-C373-458D-A0BA-947C7DF6CE6CQ36458144-0EA9FA3E-B40C-4B4E-A4A3-957CA9FAFC9EQ36686430-490178B7-4A3A-4BAF-BE4D-BBF7C354F7D9Q37162363-8881DE84-8E8F-4671-8E8A-B56AAF24D787Q37252008-FFA71E33-896B-4400-B95B-83EDE7C32986Q37663131-DDEFF59D-6A72-4604-B4DC-7E88D1000EE7Q37725318-B5B08D42-BEFD-4418-B1A8-29FDD0C7291EQ38936788-FE149B3D-846C-437F-BA53-BE475A0F88B9Q39004344-5592062C-013A-4A36-ADC3-B456CD3FFACFQ39005891-DC01DA11-70DE-40C6-AE07-14FA99BBDA90Q39092621-37EC158F-7C1A-4558-B626-81EA70F1CC51Q39326827-96299CF9-EE53-4524-BEAE-31095083647EQ41150193-C32C65A0-862D-44D3-9A3F-68C6C33A4C42Q41628269-9A4439B2-D564-4293-A0E4-7D7AC7CC3DBAQ41997119-CFD18672-685E-4F95-AA0A-D65B12122179Q42101246-D53C0B4C-CA66-4B91-854E-7819C18CD533Q42350107-55B9FB74-1C88-4E11-BDB1-19ACE5771508Q43277341-5494D08F-5D3E-4535-BE26-47F7EF0C3B75Q46002678-DB27F007-4832-4DC5-85EF-8B7C536147E4Q46174770-FF6A7A46-EF0A-4B95-9DB5-ABD5AF1BE225Q47222878-78DB4E25-1DF9-44F4-B98E-6636DF798044Q51284198-B8650D9B-674C-4DBC-A766-2058E8B8231FQ58705842-820E2AAF-688D-49FC-AC78-ED410A7CE189
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drug resistance confounding prion therapeutics.
@en
Drug resistance confounding prion therapeutics.
@nl
type
label
Drug resistance confounding prion therapeutics.
@en
Drug resistance confounding prion therapeutics.
@nl
prefLabel
Drug resistance confounding prion therapeutics.
@en
Drug resistance confounding prion therapeutics.
@nl
P2093
P2860
P50
P356
P1476
Drug resistance confounding prion therapeutics.
@en
P2093
David B Berry
Joel C Watts
Michal Geva
Sumita Bhardwaj
P2860
P304
P356
10.1073/PNAS.1317164110
P407
P577
2013-10-15T00:00:00Z